USFDA takes Ranbaxy to court
American health regulator USFDA has filed a motion in a US court seeking 'certain' documents from Ranbaxy, amid reports of systematic fraudulent conduct, which the company denied.
By PTI |
NEW DELHI: American health regulator USFDA has filed a motion in a US court seeking 'certain' documents from Ranbaxy, amid reports of systematic fraudulent conduct, which the company denied.
"No legal proceedings has been initiated against us and we continue to co-operate with the Department of Justice," a company spokesperson said.
The spokesperson, however, admitted that USFDA had filed a motion in a US court seeking certain documents.
The spokesperson refused to disclose as to what the USFDFA was seeking clarifications on from the company.
A section of the media has reported that USFDA has taken Ranbaxy to the court for systematic fraudulent conduct and has asked the court to force Ranbaxy to internally review the manufacturing operations.
The spokesperson said Ranbaxy will remain committed to supply high quality generic medicine at affordable prices the to US customers , the spokesperson added.
"No legal proceedings has been initiated against us and we continue to co-operate with the Department of Justice," a company spokesperson said.
The spokesperson, however, admitted that USFDA had filed a motion in a US court seeking certain documents.
The spokesperson refused to disclose as to what the USFDFA was seeking clarifications on from the company.
A section of the media has reported that USFDA has taken Ranbaxy to the court for systematic fraudulent conduct and has asked the court to force Ranbaxy to internally review the manufacturing operations.
The spokesperson said Ranbaxy will remain committed to supply high quality generic medicine at affordable prices the to US customers , the spokesperson added.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
